Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
Health on MSN3h
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Mounjaro is more effective for weight loss than Ozempic—how does it work? And why does it cost so much?
,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...
Compounding pharmacies can make tirzepatide again
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
Monthly Prescribing Reference6h
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.
Could weight-loss drugs boost the economy?
Weight-loss jabs could be used to help unemployed people get back to work, in a plan under consideration by Wes Streeting. Writing in The Telegraph, the health secretary said obesity was placing a ...
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Pulse5h
GPs call for urgent obesity services review as demand for new drugs rises
A group of health professionals have called for a review of obesity management services in light of increased public demand ...
Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to government
Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
Localities hit PBMs, pharma on insulin
Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.